Barbara Kulp

2.2k total citations
37 papers, 1.7k citations indexed

About

Barbara Kulp is a scholar working on Surgery, Reproductive Medicine and Oncology. According to data from OpenAlex, Barbara Kulp has authored 37 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Surgery, 19 papers in Reproductive Medicine and 13 papers in Oncology. Recurrent topics in Barbara Kulp's work include Ovarian cancer diagnosis and treatment (19 papers), Intraperitoneal and Appendiceal Malignancies (16 papers) and Chemotherapy-related skin toxicity (11 papers). Barbara Kulp is often cited by papers focused on Ovarian cancer diagnosis and treatment (19 papers), Intraperitoneal and Appendiceal Malignancies (16 papers) and Chemotherapy-related skin toxicity (11 papers). Barbara Kulp collaborates with scholars based in United States. Barbara Kulp's co-authors include Gertrude Peterson, Jerome L. Belinson, Maurie Markman, Kenneth Webster, Alexander Kennedy, Kristine Zanotti, Paul Elson, Maurie Markman, Maurie Markman and Chad M. Michener and has published in prestigious journals such as Journal of Clinical Oncology, Gynecologic Oncology and Journal of Cancer Research and Clinical Oncology.

In The Last Decade

Barbara Kulp

37 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barbara Kulp United States 20 746 582 530 474 355 37 1.7k
Gertrude Peterson United States 23 833 1.1× 671 1.2× 571 1.1× 581 1.2× 428 1.2× 50 1.9k
Suzanne Berlin United States 15 451 0.6× 408 0.7× 119 0.2× 378 0.8× 143 0.4× 37 1.3k
Gwi Eon Kim South Korea 23 74 0.1× 814 1.4× 545 1.0× 170 0.4× 69 0.2× 64 1.7k
A Fanucchi Italy 24 833 1.1× 420 0.7× 390 0.7× 49 0.1× 28 0.1× 64 1.6k
Sung Whan Ha South Korea 29 113 0.2× 892 1.5× 636 1.2× 44 0.1× 102 0.3× 126 2.1k
Charlotte Vaysse France 16 221 0.3× 293 0.5× 240 0.5× 20 0.0× 57 0.2× 66 985
I Fryatt United Kingdom 14 462 0.6× 442 0.8× 261 0.5× 18 0.0× 16 0.0× 20 1.1k
T. Hakes United States 11 403 0.5× 880 1.5× 318 0.6× 23 0.0× 188 0.5× 18 1.4k
Amanda Gordon United States 7 400 0.5× 314 0.5× 253 0.5× 25 0.1× 26 0.1× 15 801
N. Davidson United Kingdom 15 439 0.6× 1.3k 2.2× 501 0.9× 18 0.0× 27 0.1× 41 1.9k

Countries citing papers authored by Barbara Kulp

Since Specialization
Citations

This map shows the geographic impact of Barbara Kulp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Kulp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Kulp more than expected).

Fields of papers citing papers by Barbara Kulp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Kulp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Kulp. The network helps show where Barbara Kulp may publish in the future.

Co-authorship network of co-authors of Barbara Kulp

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Kulp. A scholar is included among the top collaborators of Barbara Kulp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Kulp. Barbara Kulp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peterson, Gertrude, et al.. (2005). Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecologic Oncology. 97(2). 374–378. 33 indexed citations
2.
Markman, Maurie, Kenneth Webster, Kristine Zanotti, et al.. (2004). Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. Gynecologic Oncology. 94(2). 404–408. 18 indexed citations
3.
Markman, Maurie, Fred H. Hsieh, Kristine Zanotti, et al.. (2004). Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. Journal of Cancer Research and Clinical Oncology. 130(1). 25–28. 41 indexed citations
4.
Uyar, Denise, Barbara Kulp, Gertrude Peterson, et al.. (2004). Cardiac safety profile of prolonged (≥6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecologic Oncology. 94(1). 147–151. 36 indexed citations
5.
Markman, Maurie, Barbara Kulp, & Gertrude Peterson. (2004). Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn. Gynecologic Oncology. 94(2). 578–580. 5 indexed citations
6.
Markman, Maurie, Kenneth Webster, Kristine Zanotti, et al.. (2004). Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology. 95(1). 109–113. 7 indexed citations
7.
Markman, Maurie, Kenneth Webster, Kristine Zanotti, et al.. (2004). Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers. Journal of Cancer Research and Clinical Oncology. 130(12). 741–744. 3 indexed citations
8.
Zanotti, Kristine, et al.. (2003). Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecologic Oncology. 89(3). 514–516. 48 indexed citations
9.
Zanotti, Kristine, Kenneth Webster, Jerome L. Belinson, et al.. (2003). Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecologic Oncology. 92(2). 592–595. 9 indexed citations
10.
Markman, Maurie, Kenneth Webster, Kristine Zanotti, et al.. (2003). Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecologic Oncology. 90(3). 593–596. 83 indexed citations
11.
Markman, Maurie, Barbara Kulp, Gertrude Peterson, Alexander Kennedy, & Jerome L. Belinson. (2002). Second-Line Therapy of Ovarian Cancer with Paclitaxel Administered by Both the Intravenous and Intraperitoneal Routes: Rationale and Case Reports. Gynecologic Oncology. 86(1). 95–98. 5 indexed citations
12.
13.
Markman, Maurie, et al.. (2000). Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer. Gynecologic Oncology. 79(1). 116–119. 54 indexed citations
14.
15.
Markman, Maurie, Alexander Kennedy, Kenneth Webster, et al.. (1999). An effective and more convenient drug regimen for prophylaxis gainst paclitaxel-associated hypersensitivity reactions. Journal of Cancer Research and Clinical Oncology. 125(7). 427–429. 54 indexed citations
16.
Markman, Maurie, Alexander Kennedy, Kenneth Webster, et al.. (1999). Persistent Chemosensitivity to Platinum and/or Paclitaxel in Metastatic Endometrial Cancer. Gynecologic Oncology. 73(3). 422–423. 11 indexed citations
17.
Markman, Maurie, Alexander Kennedy, Kenneth Webster, et al.. (1999). Use of Low-Dose Oral Prednisone to Prevent Paclitaxel-Induced Arthralgias and Myalgias. Gynecologic Oncology. 72(1). 100–101. 37 indexed citations
18.
Markman, Maurie, Alexander Kennedy, Kenneth Webster, et al.. (1998). Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. Journal of Cancer Research and Clinical Oncology. 124(6). 326–328. 18 indexed citations
19.
Markman, Maurie, Alexander Kennedy, Gregory P. Sutton, et al.. (1998). Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent. Gynecologic Oncology. 70(2). 272–274. 38 indexed citations
20.
Markman, Maurie, Alexander Kennedy, Kenneth Webster, et al.. (1996). Control of Carboplatin-Induced Emesis with a Fixed Low Dose of Granisetron (0.5 mg) plus Dexamethasone. Gynecologic Oncology. 60(3). 435–437. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gertrude Peterson Breakdown of academic impact, for papers by Suzanne Berlin Breakdown of academic impact, for papers by Gwi Eon Kim Breakdown of academic impact, for papers by A Fanucchi Breakdown of academic impact, for papers by Sung Whan Ha Breakdown of academic impact, for papers by Charlotte Vaysse Breakdown of academic impact, for papers by I Fryatt Breakdown of academic impact, for papers by T. Hakes Breakdown of academic impact, for papers by Amanda Gordon Breakdown of academic impact, for papers by N. Davidson
Rankless by CCL
2026